A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2013
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771370/
https://ncbi.nlm.nih.gov/pubmed/23860641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0001-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados